ABL1 and acute lymphoblastic leukemia: In patients with Philadelphia chromosome-positive (Ph+) ALL, the tyrosine kinase inhibitors that are targeting the BCR-ABL1-fused protein are effective, e.g., imatinib mesylate [162].